← Back
Data updated: Jun 28, 2026
FABRE KRAMER
Pharma Pharmaceuticals
FABRE KRAMER is a pharmaceutical company with 1 FDA-approved products.
2023
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
FDA Novel Drug Designations
(2023) 1 Novel
See 1 novel approval →
FABRE KRAMER's Key Drugs
FABRE KRAMER's core commercial portfolio centers on EXXUA — its most strategically important drugs approved in the last 15 years.
FABRE KRAMER's Recent FDA Approvals
New NDA/BLA approvals for FABRE KRAMER over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
FABRE KRAMER's Therapeutic Areas
Disease areas where FABRE KRAMER has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
FABRE KRAMER Pipeline Snapshot
Active clinical trials for FABRE KRAMER across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • EXXUA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2023-09-22
- Latest
- 2025-06-07
- Applications
- 1